Axial Spondyloarthritis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Axial spondyloarthritis (axSpA), which includes both ankylosing spondylitis (AS) and non-radiographic axial SpA, is the most common type of chronic inflammatory arthritis affecting the axial skeleton (AS). AS affects 0.1–0.5 percent of the population and is characterized by inflammatory back pain, radiographic sacroiliitis, excess spinal bone formation, and a high prevalence of HLA–B27. Although non-radiographic axial SpA shares several features with AS, advanced sacroiliac joint damage and spine ankylosis are absent. The severity of arthralgia, stiffness, and limited flexibility vary widely among patients and throughout axial SpA. The skeletal disease may be accompanied by uveitis, psoriasis, and inflammatory bowel disease (IBD). Axial SpA can impose substantial physical and social burdens on patients and interfere with day-to-day life. Axial SpA is associated with a significant disease burden, including significant pain, stiffness, and impaired physical function. Despite this burden, a substantial delay between disease onset and diagnosis and treatment often occurs, particularly in those with axial SpA lacking radiographic manifestations.

The prevalence of Axial Spondyloarthritis (axSpA) ranges from 350 to 412 cases per 100,000 population in the USA.

The competitive landscape of Axial Spondyloarthritis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Axial Spondyloarthritis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Axial Spondyloarthritis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Axial Spondyloarthritis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Namilumab       Izana Bioscience Ltd.    Phase 2

2          IL-17A  Genrix (Shanghai) Biopharmaceutical Co., Ltd.   Phase 2

3          KHK4827          Kyowa Kirin Co., Ltd.     Phase 3

4          Secukinumab    Novartis Pharmaceuticals          Phase 3

5          Bimekizumab    UCB Pharma    Phase 3

6          Ixekizumab       Eli Lilly and Company    Phase 3

7          Jitongning tablet            Tasly Pharmaceuticals, Inc.       Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more